



Florida Statistics

PCSK9 Inhibitors

About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Florida from January 2017 through December 2017.

Key Florida Findings



Rejection Rate:

29%



Appeals Rate:

27%



Final Rejections:

8,584

Of health plans that received at least 300 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- Federal Employee Benefit Plan **84%**
- Florida Blue **51%**
- Tricare Military Health SVC SYS **51%**
- Express Scripts **47%**

The following had **the lowest rates of rejection:**

- Aetna **18%**
- Humana Health Plan **12%**



The following table details claims data for the Florida managed care organizations that received at least 300 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
Federal Employee Benefit Plan	84%	489	411
Florida Blue	51%	3,164	1,621
Tricare Military Health SVC SYS	51%	563	288
Express Scripts	47%	760	355
Wellcare Management Group	33%	425	142
CVS Health	32%	2,908	932
United Health Group	28%	6,363	1,782
Cigna Healthcare	28%	1,099	304
Aetna	18%	2,251	413
Humana Health Plan	12%	5,794	676

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

